UroStream

In recent years, urology has entered an important period of rapid technological iteration and continuous evolution in treatment concepts. From the accelerated development of advanced domestically manufactured medical equipment to the growing integration of robotic-assisted surgery, molecular imaging, and artificial intelligence into clinical practice, urology is moving toward increasingly minimally invasive, precise, and function-preserving approaches. At the same time, high-quality clinical research has become an important foundation for updating treatment standards and strengthening China's academic influence in urology. Oncology Frontier – UroStream invited Professor Shaogang Wang of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, for an in-depth interview. He shared his perspectives on trends in urological development, the clinical value and technological advances of robotic-assisted surgery, and strategies for conducting high-quality clinical research.

The Pujiang Prostate Cancer Academic Conference was held in Shanghai on June 26–27, 2026. In recent years, the development of multiple innovative therapeutic approaches—including radioligand therapy, antibody-drug conjugates (ADCs), bispecific antibodies, and PARP inhibitors—has accelerated rapidly. A series of clinical studies has opened new treatment pathways for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). To systematically review the evolving landscape of prostate cancer treatment, Oncology Frontier – UroStream invited Professor Xiao Lin Lu of Fudan University Shanghai Cancer Center to share his insights.

The 2026 Pujiang Prostate Cancer Academic Conference was held in Shanghai from June 26–27, 2026. As treatment strategies for prostate cancer continue to evolve, local therapy has progressed beyond conventional radical surgery toward robot-assisted precision surgery with greater emphasis on functional preservation. Meanwhile, focal therapies such as cryoablation and irreversible electroporation (IRE) have emerged as promising treatment options for carefully selected patients.

The treatment landscape for advanced urothelial carcinoma (UC) has entered a new era. Antibody-drug conjugates (ADCs) targeting Nectin-4, HER2, and Trop-2 have rapidly transformed clinical practice, while ADCs combined with immune checkpoint inhibitors have become the new standard for first-line treatment. At the 2026 CSCO Annual Meeting, Prof. Kaiwei Yang from the Department of Urology, Peking University First Hospital presented a comprehensive overview of the current evidence supporting approved and investigational ADCs. Drawing on the latest 2026 CSCO Guidelines, he systematically reviewed first-line treatment strategies, sequencing after disease progression, breakthroughs in domestically developed ADCs, and the next generation of emerging targets, providing valuable insights into individualized treatment for advanced urothelial carcinoma.